Skip to main content Accessibility help
×
Home
Hostname: page-component-cf9d5c678-dkwk2 Total loading time: 0.246 Render date: 2021-07-27T13:21:23.490Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Impact of Antibiotic Use during Hospitalization on the Development of Gastrointestinal Colonization with Escherichia coli with Reduced Fluoroquinolone Susceptibility

Published online by Cambridge University Press:  02 January 2015

Jennifer H. Han
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
Warren B. Bilker
Affiliation:
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
Irving Nachamkin
Affiliation:
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Pam Tolomeo
Affiliation:
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
Xiangqun Mao
Affiliation:
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Neil O. Fishman
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Ebbing Lautenbach
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
Corresponding

Abstract

Objective.

Infections due to fluoroquinolone-resistant Escherichia coli (FQREC) are associated with significant morbidity and mortality. Fluoroquinolone resistance likely arises at the level of gastrointestinal colonization. The objective of this study was to identify risk factors for the development of FQREC gastrointestinal tract colonization in hospitalized patients, including the impact of antibiotics prescribed during hospitalization.

Design.

A prospective cohort study was conducted from 2002 to 2004 within a university health system.

Methods.

Hospitalized patients initially colonized with fluoroquinolone-susceptible E. coli were followed up with serial fecal sampling for new FQREC colonization or until hospital discharge or death. A Cox proportional hazards regression model was developed to identify risk factors for new FQREC colonization, with antibiotic exposure modeled as time-varying covariates.

Results.

Of 395 subjects, 73 (18.5%) became newly colonized with FQREC. Length of stay before sampling (hazard ratio [HR], 1.02 [95% confidence interval (CI), 1.1–1.03]; P = .003) and malignancy (HR, 0.37 [95% CI, 0.21–0.67]; P = .001) were significantly associated with the development of FQREC colonization. In addition, receipt of a first-generation cephalosporin (HR, 1.19 [95% CI, 1.10–1.29]; P<.001) or cefepime (HR, 1.05 [95% CI, 1.00–1.10]; P = .048) during hospitalization increased the risk of new FQREC colonization.

Conclusions.

The acquisition of FQREC in the hospital setting is complex, and antimicrobial stewardship programs should take into account patterns of antibiotic use in implementing strategies to reduce the development of new FQREC colonization. Future studies are needed to identify risk factors for infection in hospitalized patients newly colonized with FQREC.

Type
Original Article
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Linder, JA, Huang, ES, Steinman, MA, Gonzales, R, Stafford, RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259268.CrossRefGoogle ScholarPubMed
2.Lautenbach, E, Strom, BL, Nachamkin, I, et al.Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989–2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655662.CrossRefGoogle ScholarPubMed
3.Camins, BC, Marschall, J, DeVader, SR, Maker, DE, Hoffman, MW, Fraser, VJ. The clinical impact of fluoroquinolone resistance in patients with E. coli bacteremia. J Hosp Med 2011;6:344349.CrossRefGoogle ScholarPubMed
4.Lautenbach, E, Metlay, JP, Bilker, WB, Edelstein, PH, Fishman, NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005;41:923929.Google ScholarPubMed
5.Chang, TM, Lu, PL, Li, HH, Chang, CY, Chen, TC, Chang, LL. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother 2007;19:488494.CrossRefGoogle ScholarPubMed
6.Singh, R, Swick, MC, Ledesma, KR, et al.Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012;56:16801685.CrossRefGoogle ScholarPubMed
7.Kern, WV, Oethinger, M, Jellen-Ritter, AS, Levy, SB. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2000;44: 814820.CrossRefGoogle ScholarPubMed
8.Donskey, CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis 2006;43(suppl 2):S62S69.CrossRefGoogle ScholarPubMed
9.Richard, P, Delangle, MH, Raffi, F, Espaze, E, Richet, H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001;32:162166.CrossRefGoogle ScholarPubMed
10.Lautenbach, E, Fishman, NO, Bilker, WB, et al.Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:24692477.CrossRefGoogle ScholarPubMed
11.Johnson, L, Sabel, A, Burman, WJ, et al.Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008;121:876884.CrossRefGoogle ScholarPubMed
12.van der Starre, WE, van Nieuwkoop, C, Paltansing, S, et al.Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;66:650656.CrossRefGoogle ScholarPubMed
13.Huotari, K, Tarkka, E, Valtonen, V, Kolho, E. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22:492495.Google ScholarPubMed
14.Lin, CY, Huang, SH, Chen, TC, Lu, PL, Lin, WR, Chen, YH. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 2008;41:325331.Google ScholarPubMed
15.Arslan, H, Azap, OK, Ergonul, O, Timurkaynak, F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56:914918.CrossRefGoogle ScholarPubMed
16.Ortega, M, Marco, F, Soriano, A, et al.Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568574.CrossRefGoogle ScholarPubMed
17.Colodner, R, Kometiani, I, Chazan, B, Raz, R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008;36:4145.CrossRefGoogle ScholarPubMed
18.McDonald, LC, Chen, FJ, Lo, HJ, et al.Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001;45:30843091.CrossRefGoogle ScholarPubMed
19.Killgore, KM, March, KL, Guglielmo, BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004;38:11481152.CrossRefGoogle ScholarPubMed
20.Lautenbach, E, Metlay, JP, Weiner, MG, et al.Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009;30:1824.CrossRefGoogle ScholarPubMed
21.de Lastours, V, Chau, F, Tubach, F, Pasquet, B, Ruppe, E, Fantin, B. Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission. Antimicrob Agents Chemother 2010;54:51935200.CrossRefGoogle ScholarPubMed
22.Hota, BN, Pur, S, Phillips, L, Weinstein, RA, Segreti, J. Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2005;24:405410.CrossRefGoogle ScholarPubMed
23.Yagci, D, Yoruk, F, Azap, A, Memikoglu, O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009;53:12871289.CrossRefGoogle ScholarPubMed
24.Perea, S, Hidalgo, M, Arcediano, A, et al.Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother 1999;44:117120.CrossRefGoogle ScholarPubMed
25.Lautenbach, E, Fishman, NO, Metlay, JP, et al.Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006;194:7985.CrossRefGoogle ScholarPubMed
26.Gales, AC, Gordon, KA, Wilke, WW, Pfaller, MA, Jones, RN. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis 2000;36:6164.CrossRefGoogle ScholarPubMed
27.Lee, I, Fishman, NO, Zaoutis, TE, et al.Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009;169:379383.CrossRefGoogle ScholarPubMed
28.Barton, TD, Fishman, NO, Weiner, MG, LaRosa, LA, Lautenbach, E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005;26:9399.CrossRefGoogle ScholarPubMed
29.Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125137.CrossRefGoogle ScholarPubMed
30.Han, JH, Nachamkin, I, Tolomeo, P, Mao, X, Bilker, WB, Lautenbach, E. Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones. Diagn Microbiol Infect Dis 2013;76:491496.CrossRefGoogle ScholarPubMed
31.Hyle, EP, Bilker, WB, Gasink, LB, Lautenbach, E. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Control Hosp Epidemiol 2007;28:647654.CrossRefGoogle ScholarPubMed
32.Keeney, D, Ruzin, A, McAleese, F, Murphy, E, Bradford, PA. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008;61:4653.CrossRefGoogle ScholarPubMed
33.Swick, MC, Morgan-Linnell, SK, Carlson, KM, Zechiedrich, L. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob Agents Chemother 2011;55:921924.CrossRefGoogle ScholarPubMed
34.Sahm, DF, Critchley, IA, Kelly, LJ, et al.Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001;45:267274.CrossRefGoogle ScholarPubMed
35.Han, JH, Nachamkin, I, Tolomeo, P, Mao, X, Bilker, WB, Lautenbach, E. Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli. J Infect Dis 2012;206:15971603.CrossRefGoogle ScholarPubMed
36.Bolon, MK, Wright, SB, Gold, HS, Carmeli, Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother 2004;48:19341940.CrossRefGoogle ScholarPubMed
10
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Impact of Antibiotic Use during Hospitalization on the Development of Gastrointestinal Colonization with Escherichia coli with Reduced Fluoroquinolone Susceptibility
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Impact of Antibiotic Use during Hospitalization on the Development of Gastrointestinal Colonization with Escherichia coli with Reduced Fluoroquinolone Susceptibility
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Impact of Antibiotic Use during Hospitalization on the Development of Gastrointestinal Colonization with Escherichia coli with Reduced Fluoroquinolone Susceptibility
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *